Dear Editor,

We read with great interest recent reports of sensorial impairments in Covid-19 patients, both in the early \[[@CR1]\] and in a later phase of the infection \[[@CR2]\]. It is time for the scientific community to consider potential challenges and opportunities of the Covid-19 pandemic beyond clinical emergency, based on these and other observations. Among these, neurological consequences of the disease may represent an unexpected feature of translational relevance.

Indeed, infectious diseases have been associated with an increased risk of neurodegenerative and neuropsychiatric disorders \[[@CR3], [@CR4]\]. While this link may look obvious for multiple sclerosis, due to its auto-immune nature \[[@CR5]\], it is less so for disorders due to the accumulation of neurotoxic aggregates, like Parkinson's and Alzheimer's disease. Influenza epidemics are associated with neurological manifestations, and the H~5~N~1~ virus reportedly induces Parkinsonian pathology in mice, both findings possibly explained by the activation of inflammatory pathways \[[@CR4]\]. However, the exact mechanisms of these effects and whether coronaviruses show a similar action remain unclear. The current Covid-19 pandemic provides an unprecedented opportunity to disentangle the link between viral/infectious diseases, inflammation, and the risk of brain disorders, as mentioned here below.

Many Covid-19 patients present with loss of taste and olfaction \[[@CR1]\], even after the acute phase of infection \[[@CR2]\]. Hyposmia is a common symptom of different neurodegenerative and neuropsychiatric disorders \[[@CR6]\] and has been associated with levels of interleukin-6 (IL-6), an inflammatory biomarker deeply investigated in brain disorders \[[@CR7]\]. Of note, IL-6 action is blocked by tocilizumab, a drug currently used to inhibit cytokine storm in Covid-19 patients \[[@CR8]\]. A recent study revealed c-reactive protein levels above the low-grade inflammation threshold (\> 3 mg/l) for three out of four patients presenting with loss of taste and olfaction, which were reported to be more intense and long-lasting than those in common cold disease \[[@CR2]\]. Therefore, accumulating evidence suggests systemic inflammation may be a potential pathway to explain neurological sequelae of Covid-19, a hypothesis which should be investigated more in depth.

About half of hospitalized patients are \> 55 years \[[@CR9]\]: the resulting higher age-related risk of neurodegenerative disorders is a good setting to investigate triggering and double-hit mechanisms previously hypothesized for viral infections \[[@CR4]\]. The high diffusion of Covid-19 (1,873,265 ascertained cases worldwide as of April 14, 2020; <https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases>) ensures a high power to detect effects on the incident risk of brain disorders. Indeed, the rapid spread of the infection through different ethnicities and cultural and genetic backgrounds may allow planning robust multicenter studies.

To sum up, the current Covid-19 pandemic provides an extraordinary window to implement a worldwide collaborative effort, aimed at enlightening the largely unexplored relationship between viral infections, inflammation, and brain disorders. To this purpose, coordination of hospitals and general practice and public health institutions will be needed to collect, store, and allow access to electronic health records during and after the epidemic. We "call to arms" clinicians and researchers worldwide, to take an unexpected advantage from a painful event and make it an extraordinary opportunity to fight brain disorders, which represent a huge challenge and a heavy burden for national health systems.

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

AG was supported by Fondazione Umberto Veronesi.

The authors declare that they have no conflict of interest.
